SAN DIEGO--(BUSINESS WIRE)--Kurin Inc., the inventor and manufacturer of 510(k)-cleared and patented Kurin® blood culture collection sets, announced third quarter revenues increased 4.5 times over the revenue of the same period in 2018. Kurin also reports third quarter sales exceeded their total revenues for 2018.
“We want to thank our customers for their support and trust in Kurin. These forward thinking, quality driven organizations saw the value of Kurin, clinically, financially, and as part of the important fight against growing antimicrobial resistance. Since the close of 2018, we have seen strong sequential quarter over quarter growth,” said Bob Rogers, CEO of Kurin, Inc. “Kurin’s elegantly simple, intuitive design requires no additional user steps. Kurin coupled with adherence to policy is helping customers to achieve higher compliance and delivering significant reductions in false positive blood cultures. Our customer results combined with an extraordinary team of people are driving our success.”
Kurin’s revolutionary and disruptive approach to the initial specimen diversion technique, automatically and passively corrals potential contaminants during blood culture collection. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing patients to unnecessary antibiotics, extending hospital stays, and impacting larger community health issues, such as antimicrobial resistance and the life-threatening C. diff. infection.
About Kurin Inc.
Kurin Inc., a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. Kurin, manufactured in San Diego, CA, has received FDA 510(k) market clearance. For more information about Kurin, visit the website at www.kurin.com.